Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts

Clinical Cancer Research

Volumn 8, Issue 9, 2002, Pages 3000-3007

  Leggas, Markos ^a   Stewart, Clinton F ^a   Woo, Michael H ^a   Fouladi, Maryam ^a   Cheshire, Pamela J ^a   Peterson, Jennifer K ^a   Friedman, Henry S ^a   Billups, Catherine ^a   Houghton, Peter J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; ALKYLATING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BRAIN TUMOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; MAXIMUM TOLERATED DOSE; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOLID TUMOR; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; MEDULLOBLASTOMA; MICE; MICE, INBRED CBA; MICE, INBRED ICR; MICE, SCID; NEOPLASMS; NEUROBLASTOMA; NEUROECTODERMAL TUMORS, PRIMITIVE; RADIATION CHIMERA; RANDOM ALLOCATION; RHABDOID TUMOR; RHABDOMYOSARCOMA, EMBRYONAL; SESQUITERPENES; TUMOR CELLS, CULTURED; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036716830     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: A new anticancer drug
2. Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF)
3. Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines
4. Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan
5. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents
6. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S
7. Efficacy of MGI 114 (6-hydroxymethylacylfulvene. HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft
8. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model
9. Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene. HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units
10. Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft
11. Efficacy of Acylfulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: Retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells
12. Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells
13. Preclinical evaluation of illudins as anticancer agents
14. Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF. MGI 114)
15. Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF)
16. Cytotoxic effects of MGI 114 are independent of tumor p53 or p21 expression
17. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts
18. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models
19. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts
20. The direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children
21. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors
22. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts
23. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors
24. Atypical teratoid/rhabdoid tumor of the central nervous system: A highly motivated malignant tumor of infancy and childhood frequently mistaken for medulloblastoma. A Pediatric Oncology Group study
25. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood
26. Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts
27. Why drugs fail: Of mice and men revisited
28. Phase I pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies
29. Activity of irofulven (MGI 114) in patients with advanced pancreatic cancer refractory to gemcitabine
30. Dose-intensity (DI) based escalation phase I study of MGI 114 (Irofulven) exploring 3 different i. v. schedules in advanced solid tumors
31. Phase II study of irofulven (MGI 114) in platinum (P) and paclitaxel (T) resistant epithelial ovarian cancer